Reporting of adjuvant breast cancer trials: When is the right time?

Journal of Clinical Oncology

Volumn 30, Issue 1, 2012, Pages 1-2

  Earl, Helena M ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; EDITORIAL; HUMAN; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS;

EID: 84855545758     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.2747     Document Type: Editorial

References (8)

1. Joensuu H, Kellokumpu-Lehtinen P-L, Huovinen R, et al: Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: Final analysis of the randomized FinXX trial. J Clin Oncol 30:11-18, 2012
2. Joensuu H, Kellokumpu-Lehtinen P, Huovinen R, et al: Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): Efficacy in patients with triple-negative breast cancer (BC). J Clin Oncol 28:75s, 2010 (suppl 15; abstr 531)
3. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: An open-label, randomised controlled trial. Lancet Oncol 10:1145-1151, 2009
4. Poole CJ, Earl HM, Hiller L, et al: Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 355:1851-1862, 2006 (Pubitemid 44664643)
5. Earl HM, Vallier A, Hiller L, et al: Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR). J Clin Oncol 27:12s, 2009 (suppl 15; abstr 522)
6. Gregory WM, Bolland K, Whitehead J, et al: Cautionary tales of survival analysis: Conflicting analyses from a clinical trial in breast cancer. Br J Cancer 76:551-558, 1997 (Pubitemid 27331224)
7. Blows FM, Driver KE, Schmidt MK, et al: Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7:e1000279, 2010
8. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006